Glaucoma Drug Fails Trial, But Bausch + Lomb Sees Opportunity in Another Eye Disease
A Bausch + Lomb drug from a 2025 acquisition missed main and secondary objectives of a Section 2 take a ...
A Bausch + Lomb drug from a 2025 acquisition missed main and secondary objectives of a Section 2 take a ...
When clinics choose an AI companion – particularly for AI Voice Brokers – the expectation is that the device will ...
Ampreloxetine’s Section 3 failure in a number of system atrophy is the third disappointing medical trial end result for the ...
The outcomes of a randomized managed trial (RCT) point out that meningococcal B vaccine isn't efficient at stopping gonorrhea an ...
A new UCLA study reveals that a widely used federal hospital safety metric is fundamentally flawed when applied to emergency ...
Frerieke / Flickr cc A randomized clinical trial finds that the anti-inflammatory drug colchicine, once thought promising for treating COVID-19, ...
An experimental drug from Alector Inc. failed to slow the decline of patients with frontotemporal dementia in a late-stage study, ...
A Bristol Myers Squibb drug whose landmark FDA approval introduced the first novel mechanism for treating schizophrenia in decades has ...
In 2013, Google announced it would attempt to understand and ultimately slow aging through a company called Calico, a moonshot ...
Credit: Pixabay/CC0 Public Domain The U.S. is failing to keep pace with dozens of countries around the world due to ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.